{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:40:11Z","timestamp":1788212411922,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Benzimidazole opioids (nitazenes) are novel synthetic opioid receptor agonists that over the last few years have emerged on recreational drug markets, and their abuse has become a concern worldwide. In particular, limited documentation of their pharmacology and toxicology, along with their unpredictable presence in counterfeit medicines mistaken for established brands, pose significant challenges. Herein, we present a case of fatal intoxication with the nitazene etonitazepyne, after intake of tablets appearing like, and thus mistaken as, oxycodone. The assertion of etonitazepyne\u2019s implication in the case was delayed by several months, due to lack of information about and access to seized tablets. Eventually, an analytical method using liquid chromatography coupled to a Waters Xevo TQ-S tandem quadrupole mass spectrometer was developed and documented. Using this method, etonitazepyne was confirmed in the tablets and quantified at a concentration of 0.32\u2009ng\/mL in both femoral blood and vitreous fluid sampled at autopsy of the deceased. The femoral blood concentration is in the lower range compared to previously published etonitazepyne-related deaths. This case illustrates the challenges with detecting nitazenes and the imminent health risk counterfeit products poses, even for experienced drug users.<\/jats:p>","DOI":"10.1093\/jat\/bkaf065","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T12:14:11Z","timestamp":1753013651000},"source":"Crossref","is-referenced-by-count":4,"title":["Etonitazepyne in counterfeit oxycodone tablets\u2014a fatal case report"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1981-0312","authenticated-orcid":false,"given":"Live","family":"Midttun","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, St. Olav\u2032s University Hospital , Trondheim 7030,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena J","family":"Skarshaug","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, St. Olav\u2032s University Hospital , Trondheim 7030,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hege-Merete","family":"Krabseth","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, St. Olav\u2032s University Hospital , Trondheim 7030,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Ole Mobr\u00e5ten","family":"Gundersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, St. Olav\u2032s University Hospital , Trondheim 7030,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, St. Olav\u2032s University Hospital , Trondheim 7030,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne Birgitte","family":"Brekke","sequence":"additional","affiliation":[{"name":"Deparment of Pathology, St. Olav\u2032s University Hospital , Trondheim 7030,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Frost","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, St. Olav\u2032s University Hospital , Trondheim 7030,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"2026041500165263800_bkaf065-B1","author":"117th Congress (2021-2022)","year":"2024"},{"key":"2026041500165263800_bkaf065-B2","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/s2215-0366(19)30218-4","article-title":"Control of fentanyl-related substances in China","volume":"6","author":"Bao","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"2026041500165263800_bkaf065-B3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/dta.3113","article-title":"Analytical characterization of \u201cetonitazepyne,\u201d a new pyrrolidinyl-containing 2-benzylbenzimidazole opioid sold online","volume":"13","author":"Blanckaert","year":"2021","journal-title":"Drug Test Anal"},{"key":"2026041500165263800_bkaf065-B4","doi-asserted-by":"publisher","first-page":"e40736","DOI":"10.7759\/cureus.40736","article-title":"Old drugs and new challenges: a narrative review of nitazenes","volume":"15","author":"Pergolizzi","year":"2023","journal-title":"Cureus"},{"key":"2026041500165263800_bkaf065-B5","author":"United States Patent Office"},{"key":"2026041500165263800_bkaf065-B6","author":"National Center for Biotechnology Information","year":"2024"},{"key":"2026041500165263800_bkaf065-B7","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00204-022-03276-4","article-title":"Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole \u2018nitazene\u2019 synthetic opioid","volume":"96","author":"Vandeputte","year":"2022","journal-title":"Arch Toxicol"},{"key":"2026041500165263800_bkaf065-B8","author":"World Health Organization","year":"2025"},{"key":"2026041500165263800_bkaf065-B9","author":"Official Journal of the European Union","year":"2024"},{"key":"2026041500165263800_bkaf065-B10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/15563650.2021.1979235","article-title":"Severe toxicity involving N-pyrrolidino etonitazene in the United Kingdom-a case report","volume":"60","author":"Pucci","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"key":"2026041500165263800_bkaf065-B11","doi-asserted-by":"publisher","first-page":"111775","DOI":"10.1016\/j.forsciint.2023.111775","article-title":"Non-fentanyl new synthetic opioids\u2014an update","volume":"349","author":"Zawilska","year":"2023","journal-title":"Forensic Sci Int"},{"key":"2026041500165263800_bkaf065-B12","doi-asserted-by":"publisher","DOI":"10.1111\/add.70027","article-title":"Early identification of the use of potent benzylbenzimidazoles (nitazenes) through wastewater analysis: two years of data from 22 countries","author":"Bade","journal-title":"Addiction"},{"key":"2026041500165263800_bkaf065-B13","author":"The National Centre for Clinical Research on Emerging Drugs","year":"2025"},{"key":"2026041500165263800_bkaf065-B14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5694\/mja2.52605","article-title":"Responding to reports of nitazene toxicity in Australia","volume":"222","author":"Clifford","year":"2025","journal-title":"Med J Aust"},{"key":"2026041500165263800_bkaf065-B15","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2021"},{"key":"2026041500165263800_bkaf065-B16","author":"European Monitoring Centre for Drugs and Drug Addiction"},{"key":"2026041500165263800_bkaf065-B17","author":"European Monitoring Centre for Drugs and Drug Addiction"},{"key":"2026041500165263800_bkaf065-B18","author":"European Monitoring Centre for Drugs and Drug Addiction"},{"key":"2026041500165263800_bkaf065-B19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1017\/jme.2024.60","article-title":"Diverting data and drugs: a narrative review of the mallinckrodt documents","volume":"52","author":"Lentacker","year":"2024","journal-title":"J Law Med Ethics"},{"key":"2026041500165263800_bkaf065-B20","author":"Drugs.com","year":"2024"},{"key":"2026041500165263800_bkaf065-B21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/jat\/bkae076","article-title":"Identification of 5-aminometonitazene and 5-acetamidometonitazene in a postmortem case: are nitro-nitazenes unstable?","volume":"48","author":"Parks","year":"2024","journal-title":"J Anal Toxicol"},{"key":"2026041500165263800_bkaf065-B22","doi-asserted-by":"publisher","first-page":"e2331264","DOI":"10.1001\/jamanetworkopen.2023.31264","article-title":"Naloxone use in novel potent opioid and fentanyl overdoses in emergency department patients","volume":"6","author":"Amaducci","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026041500165263800_bkaf065-B23","author":"Aftenposten"},{"key":"2026041500165263800_bkaf065-B24","author":"Nettavisen"},{"key":"2026041500165263800_bkaf065-B25","author":"TV2","year":"2024"},{"key":"2026041500165263800_bkaf065-B26","author":"Oslo Universistetssykehus","year":"2024"},{"key":"2026041500165263800_bkaf065-B27","author":"NRK"},{"key":"2026041500165263800_bkaf065-B28","author":"Nettavisen"},{"key":"2026041500165263800_bkaf065-B29","author":"Global Initiative Against Transnational Organized Crime."},{"key":"2026041500165263800_bkaf065-B30","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/add.16420","article-title":"Opioid problems are changing in Europe with worrying signals that synthetic opioids may play a more significant role in the future","volume":"119","author":"Griffiths","year":"2024","journal-title":"Addiction"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkaf065\/63819285\/bkaf065.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/1\/bkaf065\/63819285\/bkaf065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/1\/bkaf065\/63819285\/bkaf065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:17:01Z","timestamp":1776226621000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/doi\/10.1093\/jat\/bkaf065\/8210464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkaf065","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,7,22]]},"article-number":"bkaf065"}}